Barclays Increases Certara (NASDAQ:CERT) Price Target to $13.00

Certara (NASDAQ:CERT) had its price target increased by Barclays from $12.00 to $13.00 in a research note released on Friday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

A number of other analysts have also weighed in on CERT. William Blair reaffirmed a “market perform” rating on shares of Certara in a research report on Thursday. Robert W. Baird decreased their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Stephens restated an “overweight” rating and set a $17.00 target price on shares of Certara in a research note on Thursday. Finally, TD Cowen initiated coverage on shares of Certara in a research note on Thursday. They issued a “buy” rating and a $16.00 price target for the company. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Certara has a consensus rating of “Hold” and a consensus target price of $15.79.

Certara Price Performance

Shares of CERT opened at $11.98 on Friday. The company has a market cap of $1.93 billion, a P/E ratio of -59.90, a PEG ratio of 9.29 and a beta of 1.57. Certara has a fifty-two week low of $9.41 and a fifty-two week high of $19.87. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm’s 50 day moving average price is $12.45 and its 200 day moving average price is $11.64.

Hedge Funds Weigh In On Certara

Several hedge funds have recently added to or reduced their stakes in the stock. ArrowMark Colorado Holdings LLC lifted its position in shares of Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after buying an additional 3,861,674 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock valued at $40,253,000 after acquiring an additional 3,387,590 shares in the last quarter. Brown Brothers Harriman & Co. purchased a new position in shares of Certara during the third quarter worth about $27,292,000. Mackenzie Financial Corp purchased a new stake in shares of Certara in the 4th quarter valued at about $17,852,000. Finally, Wasatch Advisors LP lifted its holdings in shares of Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after purchasing an additional 1,651,076 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.